Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label viscosity. Show all posts
Showing posts with label viscosity. Show all posts

Wednesday, November 25, 2020

Effects of robot viscous forces on arm movements in chronic stroke survivors: a randomized crossover study

No clue what viscosity is. Ask your doctor.

Effects of robot viscous forces on arm movements in chronic stroke survivors: a randomized crossover study

Abstract

Background

Our previous work showed that speed is linked to the ability to recover in chronic stroke survivors. Participants moving faster on the first day of a 3-week study had greater improvements on the Wolf Motor Function Test.

Methods

We examined the effects of three candidate speed-modifying fields in a crossover design: negative viscosity, positive viscosity, and a “breakthrough” force that vanishes after speed exceeds an individualized threshold.

Results

Negative viscosity resulted in a significant speed increase when it was on. No lasting after effects on movement speed were observed from any of these treatments, however, training with negative viscosity led to significant improvements in movement accuracy and smoothness.

Conclusions

Our results suggest that negative viscosity could be used as a treatment to augment the training process while still allowing participants to make their own volitional motions in practice.

Trial registration

This study was approved by the Institutional Review Boards at Northwestern University (STU00206579) and the University of Illinois at Chicago (2018-1251).

Background

Stroke neurorehabilitation often uses the unique aspects of technology to improve motor recovery. While some researchers endeavored to simply assist movement to more closely resemble healthy patterns [1,2,3], others have attempted to exploit unique capabilities of robotics or graphic feedback to encourage neuroplasticity by augmenting error [4,5,6,7,8]. Even some traditional physical therapy exercises use mirrors to get the paretic side of the body to imitate the non-paretic side [9]. These are beneficial but far from a complete cure, and it remains to be seen what strategies emerge as optimal and what might still be left undiscovered.

An alternative strategy is to first uncover the attributes associated with better clinical movement outcomes, and then target training around these [10, 11]. Our previous work [12] employed a data-driven approach to model participant improvement using metrics derived from the movements themselves. We found that participant movement speed during the initial evaluation was most predictive of clinical changes. This speed was also the most strongly correlated with changes in the Wolf Motor Function Test (WMFT), making heightened speed a possible intervention for stroke. However, before such an intervention might be tested in clinical trials, we need to establish effective methods for speeding up participants.

There are multiple possible training conditions that may achieve this increase, and here we compare three candidate classes of conditions. One approach to affect movement speed is to directly increase it with a negative viscous field; previous work [13,14,15,16] showed that training with negative viscosity can improve participant movement and movement generalization abilities. Another possibility is to leverage the motor control mechanisms of error augmentation and after effects. Under this paradigm, participants would train with positive viscosity, under the expectation that their speed would increase as an aftereffect of that training when these resistive forces are removed [6, 17]. Finally, some research has shown that combining a resistive paradigm with a reward mechanism [18] may help participants learn better. In this case, participants will move in a positive viscosity field that attempts to slow them down, but moving above a certain speed is rewarded by a “breakthrough” where resistance vanishes. Participants may bias movements towards higher speeds to avoid the resistance.

Though it is somewhat understandable why these training conditions would change participant movement speed, the change being an increase is less obvious, especially when it comes to positive viscosity and breakthrough. Many research studies have demonstrated that training under certain conditions that alter normal movement - or perception of it - will induce an aftereffect in the opposite direction. This was shown to be true for primates [19] and humans [20]. Our reasoning for including positive viscosity is that the aftereffect of slowing movement speed would be an increase in speed when the slowing forces are removed. The breakthrough condition leverages the idea of limit-push. There is some evidence that introducing a “penalty” for participant movements that are undesired, and removing that penalty when participants conform to desired movements will bias subsequent motion towards these desired patterns, this was demonstrated using robotic forces [21] and purely visual distortions [22]. By penalizing slower movements in our breakthrough condition, and rewarding faster movements with removal of that penalty, we hope to bias participant motion towards these higher speeds.

In this preliminary clinical study, we simply compared the effects of these three paradigms on participant speed. Our modest goal was to determine if it was possible to influence participants’ speed. If speed is something that can be changed, we will explore the more difficult question of its influence on functional recovery for a later trial. Chronic stroke survivors participated in a single-visit crossover trial, where they trained for a short time under these three conditions. While we were mainly interested in the direct- and after-effects of these force paradigms on participant movement speed, we examined their effects on other movement metrics as well, such as error, efficiency, and smoothness.

 

Thursday, June 4, 2020

High plasma viscosity seen in critically ill COVID-19 patients

Until you find causation I'm going to be demanding my doctor give me tPA immediately. Would an autopsy be able to determine viscosity because the autopsy results from the lungs mentioned thrombi all over the place?

High plasma viscosity seen in critically ill COVID-19 patients


Abnormally high plasma viscosity could be contributing to the thrombotic complications seen in many COVID-19 patients, a new report suggests.

Dr. Cheryl L. Maier of Emory University School of Medicine in Atlanta describe 15 COVID-19 patients with thickened blood who were admitted to their intensive-care unit in a letter in The Lancet.
"We found that the sickest patients had the highest plasma viscosity levels, more than twice normal levels," Dr. Maier told Reuters Health by email. "These levels were similar to those seen in a type of blood disorder called Waldenstrom macroglobulinemia, where the high viscosity leads to dangerous sludging of the blood in the brain and other organs."
She added, "Plasma exchange is the key treatment of hyperviscosity in diseases like Waldenstrom macroglobulinemia, but we need further studies to understand its impact on patients with COVID-19 hyperviscosity."
Fourteen of the 15 patients in the report had acute respiratory distress syndrome and were on ventilators, 14 had encephalopathy, 12 required vasopressor treatment for shock and 11 needed continuous renal replacement therapy due to failing kidneys.
Five patients with D-dimer concentrations of 3 ug/mL or above and confirmed or suspected thrombosis were given therapeutic anticoagulation. Four patients with lower D-dimer concentrations received low-dose treatment with low-molecular-weight heparin (LMWH) or subcutaneous heparin. Six who had high D-dimer concentrations but no known clotting received subtherapeutic doses of LMWH or IV heparin.
Plasma viscosity was above 95% of normal in all patients, and ranged from 1.9 to 4.2 centipoise (cP). The normal range is 1.4-1.8 cP.
Thrombotic complications occurred in all four patients who had plasma viscosity exceeding 3.5 cP, including one patient with pulmonary embolism (PE), one with limb ischemia and suspected PE, and two with clotting related to continuous renal replacement therapy.
Plasma viscosity was strongly associated with illness severity based on Plasma Viscosity and Sequential Organ Failure Assessment Scores (Pearson's r=0.84, R2=0.71, P<0.001).
"We found a strong correlation between plasma viscosity and illness severity," Dr. Maier said. "But correlation does not equal causation, and we need more studies to understand whether viscosity is simply a marker of disease or actually contributing to it. As part of this work, we're investigating what components of plasma cause the hyperviscosity."
She added, "We use plasma exchange to treat hyperviscosity in other diseases, and we're beginning to use it in some patients with COVID-19. We need larger studies to evaluate the impact of plasma exchange in COVID-19 and we're currently developing a clinical trial here at Emory."
"There's still a lot we don't know about COVID-19, and there's more going on with these atypical blood clots than we first realized," Dr. Maier said. "Hyperviscosity may be an important piece of the puzzle in linking severe inflammation to poor outcomes in COVID-19."
--Anne Harding
To read more, click here

Saturday, January 25, 2020

Progressive abduction loading therapy with horizontal-plane viscous resistance targeting weakness and flexion synergy to treat upper limb function in chronic hemiparetic stroke: A randomized clinical trial

Hope you are smarter than me. Viscous? Progressive abduction loading therapy? Try explaining that to your therapist to have them use that on you.

 

Progressive abduction loading therapy with horizontal-plane viscous resistance targeting weakness and flexion synergy to treat upper limb function in chronic hemiparetic stroke: A randomized clinical trial

Frontiers in Neurology , Volume 9(71)

NARIC Accession Number: J82535.  What's this?
ISSN: 1664-2295.
Author(s): Ellis, Michael D.; Carmona, Carolina ; Drogos, Justin ; Dewald, Julius P. A..
Project Number: 90IF0020 (formerly H133G110245).
Publication Year: 2018.
Number of Pages: 14.

Abstract: 

Study examined the therapeutic effects of horizontal-plane viscous resistance in combination with progressive abduction loading therapy. Thirty-two individuals with chronic hemiparetic stroke were randomly allocated to two groups. The two groups had equivalent baseline characteristics on all demographic and outcome metrics including age, time post stroke, and motor impairment. Both groups received therapy three times a week for 8 weeks while the experimental group included additional horizontal-plane viscous resistance. Quantitative standardized progression of the intervention was achieved using a robotic device. The primary outcomes of reaching distance and velocity under maximum abduction loading and secondary outcomes of isometric strength and a clinical battery were measured at before, after, and 3 months following therapy. There was no difference between groups on any outcome measure. However, for combined groups, there was a significant increase in reaching distance and velocity at post-testing that persisted for 3 months and also a significant increase in abduction, elbow extension, and external rotation strength at post-testing that did not persist 3 months. Similarly, the clinical battery demonstrated a significant improvement in participant-reported measures of "physical problems" and "overall recovery" across all participants. The strengthening approach of incorporating horizontal-plane viscous resistance did not enhance the reaching function improvements observed in both groups. Data do not support the postulation that one can be trained to "overpower" the flexion synergy with resistance training targeting constitutive joint torques of reaching. Instead, flexion synergy must be targeted with progressive abduction loading to improve reaching function.
Descriptor Terms: EXERCISE, LIMBS, PHYSICAL THERAPY, REHABILITATION, ROBOTICS, STROKE, THERAPEUTIC TRAINING.


Can this document be ordered through NARIC's document delivery service*?: Y.

Citation: Ellis, Michael D., Carmona, Carolina , Drogos, Justin , Dewald, Julius P. A.. (2018). Progressive abduction loading therapy with horizontal-plane viscous resistance targeting weakness and flexion synergy to treat upper limb function in chronic hemiparetic stroke: A randomized clinical trial.  Frontiers in Neurology , 9(71) Retrieved 1/25/2020, from REHABDATA database.

Wednesday, September 13, 2017

Researchers develop simple device to easily test blood viscosity

Very likely that this is incredibly important for you to know to prevent your next stroke. 

Researchers develop simple device to easily test blood viscosity


University of Connecticut researchers have developed a device that tests an important indicator of heart health that is often ignored - blood viscosity.
Blood can be a window into the health of your heart.
Doctors are often on the lookout for some common signs that might point to an issue, like abnormal cholesterol levels or high blood pressure. From heart attacks to strokes, routine blood tests can screen for several types of life-threatening cardiac events. But less attention has been paid to blood viscosity.
Viscosity measures a fluid's resistance to flow. Thick or sticky liquids like honey have high viscosity, while thin, watery liquids have low viscosity. In the case of blood, higher viscosity may signal potential problems, since the heart needs to work harder to pump sticky blood. Thick blood also means organs and tissues receive less oxygen and may cause damage to the lining of blood vessels due to increased friction as blood travels throughout the body.
Studies have shown that increased blood viscosity was significantly more prevalent in patients who experienced heart attacks and strokes compared to patients with lower blood viscosity. In fact, one study found that increased blood viscosity is a more likely sign of a potential cardiac event than high blood pressure, gender, or smoking.
Yet despite this strong correlation, physicians can't currently evaluate blood viscosity at routine office visits.
"We were very surprised that there is no commercial option to quickly and simply check this critical piece of information," says UConn Associate Professor of Mechanical Engineering and co-inventor, George Lykotrafitis. "The research shows there is a connection between blood viscosity and cardiac events, and the equipment exists to test it, but not in a practical or efficient way. We decided to try to solve the problem."
So Lykotrafitis and doctoral candidate Kostyantyn Partola developed a small electronic device that can measure blood viscosity at the point of care. The pair recently filed a provisional patent on their invention with the help of UConn's Technology Commercialization Services.
"Our technology really is plug and play, but the impact is significant," says Partola. "With this information, doctors can suggest simple life-style changes on the spot to prevent their patients from having a stroke or heart attack."
Lykotrafitis and Partola's device may be simple, but the science behind it is specialized and tailored to blood analysis.
Blood behaves as a non-Newtonian fluid, which means that its viscosity changes depending on its velocity at any given time. Since the velocity of our blood differs when pumping and at rest, its viscosity also changes.
This can be a complication for commercial instruments that are currently used to measure viscosity, but not for the device Lykotrafitis and Partola have developed.
Here's how it works. A clinician places a droplet of blood onto a small card of transparent plastic containing a microchannel. The blood wicks into the microchannel and flows through a small groove using its own capillary pressure. When the microchannel card is placed on a stage between a light source and a photodiode detector - a device that converts light into an electrical current - the device Lykotrafitis and Partola have developed measures how long it takes the blood to travel through the microchannel. A few minutes after the sample is placed on the microchannel, a digital screen displays a viscosity reading that indicates whether the patient is at elevated risk for cardiac events.
Once the test is completed, the used microchannel card is discarded and replaced with a new one. Since the device itself never comes in contact with the biological sample, practitioners don't need to sterilize it in between patients or worry about cross-contamination.
Currently, to measure blood viscosity physicians would typically need to send large samples to an off-site lab for analysis in a rheometer, an instrument that measures viscosity mechanically.
Commercial rheometers require large samples, take much longer, cost thousands of dollars, and are also commonly used to measure the viscosity of industrial liquids like oil, paint, or personal care products. The commercial equipment needs to be sterilized in between tests because of this multi-purpose capability. Travel time between the medical office where the blood was originally collected and the commercial facility where it is tested also means that samples are no longer reliable. This is all less than ideal for clinical applications.
In contrast, the device that Lykotrafitis and Partola are developing only requires a finger prick of blood, gives precise readings in just a few minutes, and will cost under a thousand dollars.
Helping scientists to "get out of the lab" and to commercialize the important technologies they develop is a major priority at UConn, according to Radenka Maric, UConn's vice president for research.
"There is a wealth of amazing ideas being developed at UConn and UConn Health every day, but to have an impact they need to reach beyond the lab" says Maric.
Partola and Lykotrafitis have formed a startup, Eir Medical Devices, based on their research. The pair are in early discussions with physicians at UConn Health and Yale University to conduct clinical trials.